Retinal Vein Occlusion Market Size Projected to Reach $4.83 billion by 2034 | 6.41%

According to Straits Research, the global Retinal Vein Occlusion Market was valued at $2.77 billion in 2025 and is projected to grow from $2.94 billion in 2026 to $4.83 billion by 2034, registering a CAGR of 6.41% during the forecast period (2026–2034).

Growing prevalence of diabetes and atherosclerosis are the major factors causing retinal vein occlusion. This can be attributed to rapidly changing dietary habits and increasing smoking activities.  More than 40 million population smoke cigarettes in the U.S., the CDC and nearly USD 170 billion is spent on medical care of smoking related conditions. Smoking is one of the major causes of hypertension, leading to RVO. Moreover, atherosclerosis is a life threating disease and around 735,000 Americans die from it every year, CDC. For many years, ophthalmologists had few options for RVO as well as diagnostic techniques. At present, increasing treatment options are showing promising outcome in the treatment of RVO. Early diagnostic techniques are also offering better management and helping in avoiding serious damage to the retina.

The prevalence of Non-ischemic CRVO is increasing

CRVO is segmented into non-ischemic and ischemic CRVO. Ischemic CRVO is more threatening than the non- ischemic as it can cause permanent blindness. Moreover, non-ischemic CRVO accounts for around 75% of cases, American Academy of Ophthalmology Organization. Diabetes and hypertension are major triggering factors to develop non-ischemic CRVO. Increasing diabetic population and its associated risk factors such as diabetic retinopathy has increased prevalence of non-ischemic CRVO worldwide. Geriatric population has been found be at the higher risk as they are more prone to diabetes. For instance, around 23.1 million adults aged 65 years or above have prediabetes in the U.S., the American Association of Diabetes Educators.

Future of European Retinal vein occlusion Market

Global retinal vein occlusion market is segmented by the Americas, Asia Pacific, Europe, and the Middle East and Africa.

Europe is the second leading retinal vein occlusion market globally due to high prevalence of disease and concentration of RVO drug manufacturers in the region. For instance, Allergen headquarters in Ireland has manufactured Ozurdex drug for the treatment of Retinal Vein Occlusion and this drug was approved by the Chinese Food and Drug Administration, and it is expected to benefit 7.4 million Chinese patients.
In addition, Bayer Pharmaceutical have also received approval for Eylea drug from the European Commission in 2018. This medication can be used for the treatment of AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO).  Moreover, increasing prevalence of RVO has coasted around USD 3.38 billion to the U.K, National Center for Biotechnology Information (NCBI).

Middle East and Africa is experiencing a steady growth in the global retinal vein occlusion market thanks to rising population of obesity, hypertension, and heart disease in the region. For instance, around 54% of the Middle Eastern population die of heart diseases, WHO. Moreover, lack of drug availability in African region may hinder the region retinal vein occlusion market growth.

Market Segments

1. By Type
   1. Branch retinal artery occlusion
   2. Central retinal vein occlusion
2. By Condition
   1. Non-ischemic
   2. Ischemic
3. By Diagnosis
   1. Optical coherence tomography (OCT)
   2. Fundoscopic examination
   3. Fluorescein angiography
   4. Others
4. By Treatment
   1. Anti-vascular endothelial growth factor
   2. Corticosteroid drugs
   3. Laser retinal photocoagulation
   4. Others
5. By End User
   1. Hospitals and clinics
   2. Research & academics centers
   3. Others
6. Regions Covered:
   1. North America
      1. U.S.
      2. Canada
      3. Mexico
   2. Europe
      1. UK
      2. Germany
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. Asia-Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Australia
      6. Rest of Asia-Pacific
   4. LAMEA
      1. Brazil
      2. Saudi Arabia
      3. South Africa
      4. Rest of LAMEA